Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label lebrikizumab in adolescents with moderate-to-severe atopic dermatitis
2019-004301-28Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lebrikizumab in atopic dermatitis (AD), sponsored by Eli Lilly and Company. Primary endpoint: Treatment discontinuation due to adverse events. Started Jul 2020; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2019-004301-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004301-28.